Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Boehringer Ingelheim
Company Location: Europe
Company Founding Year: 1885
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, China, Germany, Netherlands, Spain
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Bladder Cancer|Central Nervous System Cancer|Cervical Cancer|Esophageal Cancer|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer|Vulvar Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07744152 |
Solid Tumours | P1 |
Not yet recruiting |
Esophageal Cancer|Small Cell Lung Cancer|Head and Neck Cancer|Cervical Cancer|Non-Small-Cell Lung Cancer|Triple Negative Breast Cancer|Bladder Cancer|Central Nervous System Cancer|Vulvar Cancer|Squamous Cell Carcinoma |
2030-01-15 |
2% |
2026-08-20 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|